Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cartesian Therapeutics, Inc.

NASDAQ: RNAC · Life Sciences · 3 alerts · CIK 1453687

Share price
$6.08Close, Nov 16
Market cap
$185M
Shares outstanding
30.5MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cartesian Therapeutics, Inc. filings on SEC EDGAR ↗

7:08 AM ET 8-K
Financial Results

Cartesian Therapeutics Financial Results

Cartesian Therapeutics reported Q3 2026 financial results, ending the period with $124.7 million in cash to support operations into 2028. The company is advancing its Phase 3 AURORA trial for Descartes-08 in myasthenia gravis with data expected in Q1 2027 and a BLA filing planned for mid-2027.

Term
Q3 2026

“With Phase 3 AURORA data expected in the first quarter of 2027, our focus this quarter remains on execution, both in the clinic and in preparing the organization for a commercial launch. Ahead of our anticipated BLA submission in mid-2027, we have expanded our medical affairs and commercial teams to drive launch readiness.”

Carsten Brunn, Ph.D., President and Chief Executive Officer
7:06 AM ET 10-Q
Financial Results

Cartesian Therapeutics Q3 2026 Results: Net Loss of $11.5M, Loss Narrows

Cartesian Therapeutics reported its third-quarter 2026 results, highlighting continued investment in its mRNA cell therapy pipeline, specifically lead candidate Descartes-08. The company maintained a strong cash position to fund operations into 2027, despite a net loss driven by increased clinical trial expenses.

Key figure
Net loss $11.5M
7:36 AM ET 8-K
Clinical Trial Data

Cartesian Therapeutics Clinical Trial Data

Cartesian Therapeutics announced positive 12-month retreatment data from its Phase 2 trial of Descartes-08 in patients with myasthenia gravis (MG). The data showed that patients who were retreated after symptom recurrence experienced deep and durable responses, with a mean MG-ADL score reduction of 6.6 points at 12 months and no new safety signals. Topline data from the Phase 3 AURORA trial is expected in the first quarter of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.